Cyteir Therapeutics, Inc. (CYT)


Stock Price Forecast

March 19, 2024


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading Cyteir Therapeutics, Inc. chart...

About the Company

We do not have any company description for Cyteir Therapeutics, Inc. at the moment.

Sector

Life Sciences

Industry

Pharmaceutical Preparations

Employees

42

Exchange

Nasdaq

$M

Total Revenue

42

Employees

$109M

Market Capitalization

-3.34

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $CYT News

Cyteir Therapeutics Inc CYTT

2d ago, source: Morningstar

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Cyteir Announces Timeline for Voluntarily Delisting from Nasdaq

1mon ago, source: Stockhouse

Cyteir Therapeutics, Inc. (“Cyteir”) (Nasdaq: CYT) today announced that it has formally notified The Nasdaq Stock Market (“Nasdaq”) of its intent to delist ...

Cyteir Therapeutics, Inc. Common Stock (CYT)

2y ago, source: Nasdaq

© 2023 EDGAR®Online LLC, a subsidiary of OTC Markets Group. All rights reserved. EDGAR® and SEC® are trademarks of the U.S. Securities and Exchange Commission ...

Cyteir Therapeutics executive buys $503k in company stock

25d ago, source: Investing

Cyteir Therapeutics, Inc. (NASDAQ:CYT) has reported a significant purchase of its shares by a top executive, according to a recent filing with the Securities and Exchange Commission. Braden ...

Cyteir Therapeutics (CYTT) Earnings Dates & Reports

23d ago, source: Investing

View upcoming earnings forecasts and in-depth analysis of company forecasts.

Cyteir Therapeutics to delist from Nasdaq

1mon ago, source: Investing

LEXINGTON, Mass. - Cyteir Therapeutics, Inc. (NASDAQ:CYT), a biotechnology company, announced its decision to voluntarily delist its common stock from the Nasdaq Global Select Market. The company ...

ELYM Eliem Therapeutics, Inc.

8d ago, source: Seeking Alpha

Eliem Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in chronic pain, psychiatry ...

Cyteir Therapeutics, Inc. (CYTT)

29d ago, source: Nasdaq

Insider Trading information for NDAQ is derived from Forms 3 and 4 filings filed with the U.S. Securities and Exchange Commission (SEC). Please Note:An FPI is exempt of filing insider holdings ...

Cyteir Therapeutics, Inc. (CYTT)

1mon ago, source: Yahoo Finance

*Close price adjusted for splits.**Adjusted close price adjusted for splits and dividend and/or capital gain distributions. Loading more data ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...